FIG. 5.

Protection against recurrent lesions and disease. HSV-2-challenged guinea pigs were scored for disease during the recurrent phase of infection, defined as days 15 to 100 postchallenge. (A) A lesion day was scored for a guinea pig that developed at least one lesion (disease score of 2 or rarely 3), and the cumulative number of lesion days for each vaccine group was averaged over the number of guinea pigs in each group. The pVAX-FI-HSV2 group, UL29, UL52, gD2t DNA-FI-HSV2 group, and gD2 subunit group each had 10 guinea pigs. The UL5, UL30, gD2t DNA-FI-HSV2 group had 9 guinea pigs, and as shown in Table 2 and as described in the text, the pVAX-FI-Mock group had 6 guinea pigs until day 34 and then 5 guinea pigs through day 100. (B) Each symbol represents the number of days in the recurrent phase that an individual (Indiv.) guinea pig had a score of 0.5 or above, and the vaccine group means are shown by the short horizontal lines. Note that the guinea pig in the pVAX-FI-Mock group that died on day 34 had resolved its primary disease and then accumulated 16 recurrent disease days before death. This was in contrast to an additional animal in this group that was omitted from the recurrent-phase study since it never resolved its primary disease. Values that were significantly different (P < 0.05) from the value for the control group (pVAX-FI-Mock) by Kruskal-Wallis analysis plus Dunn's multiple-comparison tests are indicated (*).